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Abstract 
The market of new psychoactive substances (NPS) is characterized by a high turnover and 
thus provides several challenges for analytical toxicology. The analysis of urine samples often 
requires detailed knowledge about metabolism given that parent compounds may either be 
present only in small amounts or may not even be excreted. Hence, knowledge of the 
metabolism of NPS is a prerequisite for the development of reliable analytical methods. The 
main aim of this work was to elucidate for the first time the pooled human liver S9 fraction 
metabolism of the nine d-lysergic acid diethylamide (LSD) derivatives 1-acetyl-LSD (ALD-
52), 1-propionyl-LSD (1P-LSD), 1-butyryl-LSD (1B-LSD), N6-ethyl-nor-LSD (ETH-LAD), 
1-propionyl-N6-ethyl-nor-LSD (1P-ETH-LAD), N6-allyl-nor-LSD (AL-LAD), N-ethyl-N-
cyclopropyl lysergamide (ECPLA), (2’S,4’S)-lysergic acid 2,4-dimethylazetidide (LSZ), and 
lysergic acid morpholide (LSM-775) by means of liquid chromatography coupled to high 
resolution tandem mass spectrometry. Identification of the monooxygenase enzymes involved 
in the initial metabolic steps was performed using recombinant human enzymes and their 
contribution confirmed by inhibition experiments. Overall, N-dealkylation, hydroxylation, as 
well as combinations of these steps predominantly catalyzed by CYP1A2 and CYP3A4 were 
found. For ALD-52, 1P-LSD, and 1B-LSD deacylation to LSD was observed. The obtained 
mass spectral data of all metabolites is essential for reliable analytical detection particularly in 
urinalysis and for differentiation of the LSD-like compounds as biotransformations also led to 
structurally identical metabolites. However, in urine of rats after the administration of 
expected recreational doses and using standard urine screening approaches, parent drugs or 
metabolites could not be detected.  
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Introduction 
The discovery of the potent psychoactive effects of d-lysergic acid diethylamide (LSD, see 
Fig. 1) in 1943 triggered a new era in psychopharmacological research and subsequently 
became a household name in popular culture [1]. For the purpose of extending the knowledge 
of lysergamide-based structure-activity relationships, several LSD-based substances have 
been investigated [2-9]. In recent years, a renewed interest in the use of LSD within the 
clinical context emerged as documented by increasing numbers of studies involving human 
volunteers [10-12]. At the same time, a number of LSD-based substances appeared as 
‘research chemicals’ on the new psychoactive substances (NPS) market, predominantly in the 
form of blotters and powders. These substances included 1-acetyl-LSD (ALD-52), 1-
propionyl-LSD (1P-LSD) [13], 1-butyryl-LSD (1B-LSD), N6-ethyl-nor-LSD (ETH-LAD) 
[14], 1-propionyl-ETH-LAD (1P-ETH-LAD) [14], N6-allyl-nor-LSD (AL-LAD) [15], N-
ethyl-N-cyclopropyl lysergamide (ECPLA) [16], (2’S,4’S)-lysergic acid 2,4-dimethylazetidide 
(LSZ) [15], and lysergic acid morpholide (LSM-775) [17] (Fig. 1). 
NPS in general were reported to the EU Early Warning System at a rate of one per week 
in 2016 being a big issue in forensic or clinical toxicology and the health care system in 
general [18]. The ability to detect newly emerging drugs of abuse in samples obtained from 
biological matrices requires the development of reliable screening methods. Particularly the 
analysis of urine samples benefits from knowing the drug’s metabolic transformation patterns, 
especially in cases where the parent compound may only be present in small amounts or not 
even be excreted. In case of LSD, its metabolite 2-oxo-3-hydroxy LSD was reported to be 
present at higher concentrations and detectable for a longer time than LSD itself in urine 
samples of LSD users [19]. The detection of 2-oxo-3-hydroxy LSD in urine has been 
subsequently described as part of some clinical investigations [20, 21]. In vivo studies in 
rodents or in vitro studies using human hepatocytes or human liver cell fractions such as 
pooled human liver microsomes (pHLM) or pooled human liver S9 (pS9) are established tools 
for metabolite formation and subsequent identification [22-25]. Several studies showed 
comparable metabolic profiles to human urine samples [26-28]. To date, no information on 
the phase I and II metabolism of the nine LSD derivatives investigated in this study is 
available. Therefore, the aim of the present study was first to identify the main in vitro phase I 
and II metabolites of ALD-52, 1P-LSD, 1B-LSD, ETH-LAD, 1P-ETH-LAD, AL-LAD, 
ECPLA, LSZ, and LSM-775 for toxicological screening purposes using pS9 incubations and 
subsequent analysis by liquid chromatography coupled to high resolution tandem mass 
spectrometry (LC-HRMS/MS). LSD was also investigated and results compared to literature 
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to aid development of the experimental conditions. In addition, the monooxygenase enzymes 
involved in the initial metabolic steps were investigated to assess the potential impact of 
interindividual variations that may occur during metabolism or as a consequence of drug-drug 
and drug-food interactions. As no information about the monooxygenases involved in the 
metabolism of LSD is available so far, it was also included in this study. Finally, detectability 
studies using rat urine collected after the administration of expected recreational doses of the 
LSD-based NPS and standard urine screening approaches (SUSAs) were conducted. 
 
Experimental 
Chemicals and enzymes 
ALD-52, 1P-LSD, 1B-LSD, ETH-LAD, 1P-ETH-LAD, AL-LAD, ECPLA, LSZ, and LSM-
775 were available from previous studies and provided by Synex Synthetics (Maastricht, The 
Netherlands). LSD and LSD-d3 were supplied by LGC Standards (Wesel, Germany). 
Isocitrate, isocitrate dehydrogenase, superoxide dismutase, 3’-phosphoadenosine-5’-
phosphosulfate (PAPS), S-(5’-adenosyl)-L-methionine (SAM), dithiothreitol (DTT), reduced 
glutathione (GSH), carnitine acetyltransferase, acetylcarnitine, acetyl coenzyme A (AcCoA), 
magnesium chloride (MgCl2), potassium dihydrogenphosphate (KH2PO4), dipotassium 
hydrogenphosphate (K2HPO4), Tris hydrochloride, ketoconazole, and alpha-naphthoflavone 
from Sigma-Aldrich (Taufkirchen, Germany), and NADP+ were from Biomol (Hamburg, 
Germany). Acetonitrile (LC-MS grade), ammonium formate (analytical grade), formic acid 
(LC-MS grade), methanol (LC-MS grade), and all other chemicals and reagents (analytical 
grade) were from VWR (Darmstadt, Germany). The baculovirus-infected insect cell 
microsomes (Supersomes) containing 1 nmol/mL of human cDNA-expressed CYP1A2, 
CYP2A6, CYP2B6, CYP2C8, CYP2C9 (2 nmol/mL), CYP2C19, CYP2D6, CYP2E1 
(2 nmol/mL), CYP3A4, CYP3A5 (2 nmol/mL), or FMO3 (5 mg protein/mL), and pHLM 
(20 mg microsomal protein/mL, 330 pmol total CYP/mg protein), pS9 (20 mg microsomal 
protein/mL), UGT reaction mixture solution A (25 mM UDP-glucuronic acid), and UGT 
reaction mixture solution B (250 mM Tris HCl, 40 mM MgCl2, and 125 µg/mL alamethicin) 
were obtained from Corning (Amsterdam, The Netherlands). After delivery, the enzymes and 
liver cell preparations were thawed at 37 °C, aliquoted, snap-frozen in liquid nitrogen, and 
stored at -80 °C until use. LSD and all other lysergamide test drugs were dissolved in 
methanol at a concentration of 1 mg/mL, each, and stored at -20 °C. 
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In vitro incubations for metabolism studies 
As previously described by Richter et al. [29], the final incubation volume was 150 µL. 
Incubations were performed using pS9 (2 mg microsomal protein/mL) after preincubation for 
10 min at 37 °C with 25 µg/mL alamethicin (UGT reaction mixture solution B), 90 mM 
phosphate buffer (pH 7.4), 2.5 mM Mg2+, 2.5 mM isocitrate, 0.6 mM NADP+, 0.8 U/mL 
isocitrate dehydrogenase, 100 U/mL superoxide dismutase, 0.1 mM AcCoA, 2.3 mM 
acetylcarnitine, and 8 U/mL carnitine acetyltransferase. Thereafter, 2.5 mM UDP-glucuronic 
acid (UGT reaction mixture solution A), 40 µM PAPS, 1.2 mM SAM, 1 mM DTT, 10 mM 
GSH, and 25 µM substrate (LSD or analog) were added. All given concentrations are the final 
concentrations in one reaction tube. The organic solvent content in the final incubation 
mixtures was always below 1% [30]. The reaction was initiated by addition of substrate and 
the reaction mixture was incubated for a maximum of 480 min. After 60 min, an aliquot of 
60 µL of the incubation mixture was transferred to a reaction tube containing 20 µL ice-cold 
acetonitrile for termination of the reactions. The remaining mixture was incubated for 
additional 420 min and thereafter stopped by addition of 30 µL ice-cold acetonitrile. 
Afterwards, mixtures were cooled for 30 min at -18 °C, centrifuged for 2 min at 10.000 x g, 
and a volume of 60 µL of the supernatants transferred into autosampler vials, followed by 
injection of 1 µL onto the LC-HRMS/MS system. Blank samples without substrate and 
control samples without pS9 were prepared to confirm the absence of interfering compounds 
and to identify compounds not formed by metabolism, respectively. All incubations were 
performed in duplicates (n = 2). 
 
 
Monooxygenases activity screening and inhibition studies using selective CYP inhibitors  
According to previously published procedures [31], microsomal incubations (n = 2 each) were 
performed at 37 °C for 30 min using a substrate concentration of 25 µM (LSD or analog) and 
CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, 
CYP3A5 (75 pmol/mL each), or FMO3 (0.25 mg protein/mL). Reference incubations with 
pHLM (1 mg microsomal protein/mL) were used as positive control. Control samples without 
enzymes were prepared to assess formation of compounds that did not originate from 
metabolism. Besides enzymes and substrates, the incubation mixtures (final volume, 50 µL) 
contained 90 mM phosphate buffer (pH 7.4), 5 mM Mg2+, 5 mM isocitrate, 1.2 mM NADP+, 
0.5 U/mL isocitrate dehydrogenase, and 200 U/mL superoxide dismutase. For incubations 
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with CYP2A6 or CYP2C9, phosphate buffer was replaced with 90 mM Tris buffer, 
respectively, according to the manufacturer’s recommendation. Reactions were initiated by 
addition of the enzyme preparation and terminated by addition of 50 µL of ice-cold 
acetonitrile, containing 5 µM LSD-d3 as internal standard. The mixture was centrifuged for 
2 min at 18,407 x g (rcf). Seventy µL of the supernatant were transferred into an autosampler 
vial and 1 µL was injected onto the LC-HRMS/MS system. 
According to a previous study [32], the influence of ketoconazole (CYP3A4 inhibitor), alpha-
naphthoflavone (CYP1A2 inhibitor), or a mixture of them (1 µM, respectively) on the 
formation of monooxygenase-dependent metabolites was assessed using pHLM (1 mg 
microsomal protein/mL), 25 µM substrate (LSD or one of the analogs), and LSD-d3 as 
internal standard. All incubations were performed at 37 °C for 20 min with six replicates in 
each test set. All other incubation settings were the same as described for the monooxygenase 
activity screening. As measure of the metabolite formation in reference incubations without 
inhibitor, peak areas of all metabolites were summed up and divided by the peak area of the 
internal standard. This was also done for control incubations without pHLM and peak area 
ratios were subtracted from that in reference incubations. The result was referred to as 100% 
and compared to peak area ratios in test incubations with inhibitor. Significance of inhibition 
was tested using a one-way ANOVA followed by Dunnett's multiple comparison test 
(significance level, P < 0.001, 99.9% confidence intervals) by GraphPad Prism 5.00 software 
(GraphPad Software, San Diego, USA).  
 
LC‐HRMS/MS instrumentation  
A Thermo Fisher Scientific (TF, Dreieich, Germany) Dionex UltiMate 3000 Rapid Separation 
(RS) UHPLC system with a quaternary UltiMate 3000 RS pump and an UltiMate 3000 RS 
autosampler was used, controlled by the TF Chromeleon software version 6.80, and coupled 
to a TF Q-Exactive Plus equipped with a heated electrospray ionization II source (HESI-II). 
Mass calibration was performed prior to analysis according to the manufacturer’s 
recommendations using external mass calibration. Gradient elution was performed on a TF 
Accucore PhenylHexyl column (100 mm x 2.1 mm inner diameter, 2.6 µm particle size). The 
mobile phases consisted of 2 mM aqueous ammonium formate containing formic acid (0.1%, 
v/v) and acetonitrile (1%, v/v, pH 3, eluent A) and 2 mM ammonium formate in 
acetonitrile/methanol (50:50, v/v) containing formic acid (0.1%, v/v) and water (1%, v/v, 
eluent B). The gradient and flow rate were programmed as follows: 0-10 min 10% B to 50% 
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B, 10-12 min hold 98% B, and 12-14 min hold 10% B, constantly at a flow rate of 
0.5 mL/min. HESI-II conditions have been employed as described previously by Wagmann et 
al. [33]: heater temperature, 438 °C; ion transfer capillary temperature, 269 °C; sheath gas, 53 
arbitrary units (AU); auxiliary gas, 14 AU; sweep gas, 3 AU; spray voltage, 3.50 kV, and S-
lens RF level, 60.0. Mass spectrometric analysis was performed in positive full scan mode 
and targeted MS2 mode using an inclusion list. Pick others mode was activated to ensure the 
recording of MS2 spectra of precursor ions not in the inclusion list. The settings for full scan 
data acquisition were as follows: resolution, 35 000; automatic gain control (AGC) target, 
1e6; maximum injection time (IT), 120 ms; scan range, m/z 100-700. The settings for the 
targeted MS2 mode using an inclusion list were as follows: resolution, 17 500; AGC target, 
2e5; maximum IT, 250 ms; isolation window, m/z 1.0; high collision dissociation cell with 
stepped normalized collision energy, 17.5, 35.0, 52.5. TF Xcalibur Qual Browser software 
version 2.2 SP1.48 was used for data evaluation. 
Collection of rat urine samples for detectability studies 
In accordance to previous publications [34], the in vivo studies were performed using rat 
urine samples from male Wistar rats (Charles River, Sulzfeld, Germany) for toxicological 
diagnostic reasons according to corresponding German law (Bundesministerium der Justitz 
und für Verbraucherschutz, http://www.gesetze-im-internet.de/tierschg/index.html). Before 
drug administration, blank urine was collected over a period of 24 h. Animals had water ad 
libitum during collection of urine over a 24 h period and were housed in a metabolism cage. 
Urine was collected separated from feces. For the detectability studies, doses of 0.01 mg/kg 
body weight (BW) were administered. The urine samples were analyzed directly and 
remaining was aliquoted and stored at -20 °C.  
Rat urine analysis by LC-HRMS/MS, LC-linear ion trap MS, and gas chromatography-
MS 
To check the detectability and analytical differentiation of the LSD-based NPS after estimated 
recreational user´s dose administrations, three SUSAs were performed. The settings were 
used as described in the given references for the LC-HRMS/MS [35], LC linear ion trap MS 
(LC-MSn) [36, 37], and gas chromatography (GC)-MS [38, 39] SUSAs. Briefly, the following 
sample preparations were used: a simple urine precipitation with acetonitrile for the LC-based 
SUSAs and a liquid-liquid extraction after acidic hydrolysis followed by and acetylation for 
the GC-MS SUSA. Detection limits for LSD and its derivatives by the aforementioned 
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methods was studied using methanolic pure substance solutions at various concentrations 
(0.1, 1, 10, and 100 ng/mL). The lowest concentration resulting in an MS2 spectrum was 
defined as limit of identification (LOI). 
 
Results and discussion 
Identification of metabolites 
Human metabolites of LSD were already described [19, 40-43]. To confirm suitable 
incubation conditions and detection methods concerning the in vitro assay, LSD was also 
incubated with pS9 and analyzed by LC-HRMS/MS. In general, MS1 data was screened for 
potential exact precursor masses (PM) of expected metabolites. Afterwards, the fragmentation 
pattern in the MS2 spectrum was interpreted and compared to that of the parent compound for 
confirmation and possible assignment of the position. This procedure was the same for LSD 
and its analogs.  
The lysergamide test drugs and all identified phase I and II metabolites are listed in 
Table 1, which contains their ID, the calculated exact mass of the protonated precursor 
(M+H+), elemental composition, determined retention time (RT) and three most abundant 
fragment ions (FI) in MS2. In total, the pS9 incubations resulted in detection of several 
tentative metabolites. LSD: six metabolites; ALD-52: seven metabolites; 1P-LSD: eight 
metabolites; 1B-LSD: seven metabolites; ETH-LAD: five metabolites; 1P-ETH-LAD: seven 
metabolites; AL-LAD: eleven metabolites; ECPLA: eight metabolites; LSZ: nine metabolites, 
and LSM-775: four metabolites.  
The LSD metabolites were comparable to those described before: N-deethyl LSD (ID 2, 
also referred to as lysergic acid monoethylamide, LAE) and N6-demethyl LSD (ID 3, also 
referred to as nor-LSD) could be unambiguously identified. Two hydroxy LSD isomers were 
detected, but it has to be stated that the final positions of the hydroxy groups could not be 
determined based on fragmentation patterns. However, hydroxy LSD isomer 2 (ID 5) and the 
corresponding glucuronide (ID 7) are expected to be the same as described by Steuer et al. in 
plasma samples [42] based on their fragmentation. Dihydroxy LSD (ID 6) is expected to be 
the same compound referred to as 2-oxo-3-hydroxy LSD elsewhere, which is widely known 
as main metabolite of LSD [19, 20, 44-46]. Only the hydroxy LSD isomer with the hydroxy 
group located at the diethylamide part of the molecule (also referred to as lysergic acid ethyl-
hydroxy ethylamide, LEO) and trihydroxy LSD were described to be present as minor signals 
in human plasma or urine but not detected in the in vitro pS9 incubations. However, it should 
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be kept in mind that quantitative determinations of the metabolites' concentrations were 
beyond the scope of this study. Under the investigated conditions, these two metabolites 
might have been formed in concentrations below detectability or the chosen incubation time 
was not sufficient for their formation, as multistep reactions were already described to need a 
longer incubation time [47]. Furthermore, LSD hydroxy isomer 1 (ID 4) was expected to be 
hydroxylated in position 4 or 5 due to the fragmentation pattern, which was not described 
before (discussed in detail below for 1-depropionyl hydroxy 1P-LSD isomer 1, ID 4). Iso-
LSD, a diastereomer of LSD, which is formed during the production of LSD under basic 
conditions, was previously used as additional marker for LSD consumption and shown to be 
metabolized in the human body. The spectra of LSD and iso-LSD differed only in the 
intensity of particular FI [42]. For several LSD-based NPS, a smaller signal with the same 
mass could be detected eluting after the parent compound. The MS2 only showed differences 
in the intensity of some FI and therefore, these signals were expected to be generated by the 
iso-forms. However, due to the lack of reference material, their identity could not be 
confirmed. 
Due to the large number of LSD-based drugs used during this study, some 
representative examples were chosen to illustrate the general identification procedure. 
Furthermore, all compounds and their metabolites showed comparable fragmentation patterns. 
The procedure used for the tentative identification of the metabolites based on the HRMS/MS 
spectra was employed according to the example described for 1P-LSD (ID 11). Brandt et al. 
previously published an MS2 spectrum of 1P-LSD recorded using electrospray ionization 
accurate mass quadrupole time of flight tandem mass spectrometry [13]. The observed 
fragmentation pattern corresponded to the MS2 spectrum of 1P-LSD using orbitrap-based 
tandem mass spectrometry. The MS2 spectra of LSD (ID 1) and 1P-LSD (ID 11) can be found 
in Fig. 2. Briefly, the FI at m/z 337.1910 (C21H25N2O2+) formed after loss of N-
methylmethanimine (C2H5N) and the FI at m/z 279.1491 (C18H19N2O+) formed after loss of 
N,N-diethylformamide (C5H11NO) from the protonated molecule (C23H30N3O2+) were 
characteristic for 1P-LSD and allowed for a differentiation of the MS2 spectrum of LSD since 
both FI carried the additional 1-propionyl moiety (C3H5O). These FI correspond to the FI at 
m/z 281.1648 (C18H21N2O+) and at m/z 223.1229 (C15H15N2+) detected in the MS2 spectrum of 
LSD (Fig. 2). The last-named FI (m/z 223.1229) represented the N6-methylated 9,10-
didehydroergoline core and was the FI with the highest abundance in the MS2 spectrum of 1P-
LSD, most probably formed after elimination of the N1-propionyl moiety from the FI at m/z 
279.1491. Also, the FI at m/z 208.0756 (C14H10NO+) had a high abundance and was also 
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detectable in the MS2 spectrum of LSD. However, it has to be mentioned that a second FI 
with the nominal mass of m/z 208 but the exact mass of at m/z 208.0995 (C14H12N2+) was 
detectable with a comparable abundance to 208.0756 in both spectra, which was most 
probably formed after loss of methyl (CH3) from FI at m/z 223.1229. In addition, the FI at m/z 
128.1069 (C7H14NO+) and m/z 74.0964 (C4H12N+) representing the diethylamide part were 
detectable in the spectra of 1P-LSD and LSD. The HRMS/MS spectra of all parent 
compounds and the most abundant, unique metabolites after pS9 incubation allowing the 
identification of the parent compound (with exception of the ETH-LAD metabolite that could 
also be formed after intake of 1P-ETH-LAD) can be found in the electronic supplementary 
material in Fig. S1. 
In total, eight metabolites of 1P-LSD were identified in the pS9 incubations (see Table 
1). 1-Depropionylation led to the formation of LSD (ID 1, PM at m/z 324.2070). Therefore, 
1P-LSD can be considered as LSD prodrug, which was consistent with preliminary data 
reported by Brandt et al. who incubated 1P-LSD in human serum [13]. An additional N-
deethylation led to formation of 1-depropionyl-N-deethyl 1P-LSD (ID 2, PM at m/z 
296.1757). The loss of an ethylene group (- 28.0313 u, C2H4) resulted in the FI at m/z 
253.1335 (C16H17N2O+) in comparison to m/z 281.1648 in the MS2 spectrum of LSD. Other 
FI, for example at m/z 223.1229 or m/z 208.0756 remained unchanged, whereas the FI at m/z 
74.0964 was not detectable in the MS2 spectrum of 1-depropionyl-N-deethyl 1P-LSD (ID 2). 
N6-demethylation instead of N-deethylation resulted in formation of 1-depropionyl-N6-
demethyl 1P-LSD (ID 3, PM at m/z 310.1913). The FI at m/z 223.1229 was shifted to m/z 
209.1073 (C14H13N2+) corresponding to the loss of methylene (- 14.0156 u, CH2). Other FI, 
for example at m/z 281.1648 or m/z 74.0964 were unchanged compared to LSD. Two isomers 
of 1-depropionyl-hydroxy 1P-LSD (ID 4 and 5, PM at m/z 340.2019) were detectable. In the 
MS2 spectrum of isomer 1 (ID 4, RT 3.4 min, Fig. 2), an initial loss of water (- 18.0105 u, 
H2O) was detectable. Therefore, 1-depropionyl-hydroxy 1P-LSD isomer 1 was expected to 
carry an aliphatic hydroxy group. Based on the fragmentation pattern, a hydroxylation at the 
diethylamide part can be excluded because the FI at m/z 74.0964 was present in the MS2 
spectrum. Due to the detection of m/z 297.1597 (C18H21N2O2+), a hydroxylation at the N6-
methyl group and position 7 can be excluded, which led to the indication that the hydroxy 
group might have been located at position 4 or 5. However, an unambiguous assignment was 
not possible based on the fragmentation pattern in the MS2 spectrum. In case of 1-
depropionyl-hydroxy 1P-LSD isomer 2 (ID 5, RT 3.6 min) no water loss was detectable and 
the hydroxy group should therefore most likely be located at an aromatic position [48]. The FI 
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at m/z 74.0964 and m/z 297.1597 were both present. Due to these FI, the hydroxy group is 
most probably located at the indole part of the 9,10-didehydroergoline core. Furthermore, 1-
depropionyl-dihydroxy 1P-LSD (ID 6, PM at m/z 356.1968) was detected with one aliphatic 
and one aromatic hydroxy group. Due to the fragmentation pattern, this metabolite could be 
the result of the combination of both monohydroxy isomers (ID 4 and 5). However, the 
metabolite 2-oxo-3-hydroxy LSD was reported to be the main urinary excretion product of 
LSD [19, 41]. Possible metabolic pathways resulting in its formation were discussed by Klette 
et al. [40]. Nevertheless, its protonated mass at m/z 356 corresponds to the mass of 1-
depropionyl-dihydroxy 1P-LSD (ID 6). Also the prominent FI at m/z 237 and m/z 338 
described by Klette et al. were present in the spectrum of 1-depropionyl-dihydroxy 1P-LSD 
(ID 6). Due to this fact and the proposed fragmentation pattern, both compounds were 
expected to be identical. The aforementioned metabolites of 1P-LSD were also found in 
incubations with LSD and are therefore not suitable as urinary markers to discriminate 
between the intake of LSD and 1P-LSD. In general, structurally identical metabolites have the 
same ID in Table 1 to highlight these observations. Nevertheless, two 1P-LSD metabolites not 
evolved from LSD were identified. These metabolites were formed from 1P-LSD by N-
deethylation (ID 12, PM at m/z 352.2019) and N6-demethylation (ID 13, PM at m/z 366.2176), 
respectively. In case of N-deethyl 1P-LSD (ID 12, Fig. 2), the FI at m/z 309.1597 
(C19H21N2O2+) corresponded to the FI at m/z 337.1910 in the spectrum of 1P-LSD shifted by - 
28.0313 u, the loss of an ethylene group (C2H4). The FI at m/z 279.1491 was unchanged. In 
case of N6-demethyl 1P-LSD (1P-nor-LSD) (ID 13), the FI at m/z 279.1491 was shifted by -
14.0156 u due to the loss of methylene (CH2) while the FI at m/z 337.1910 was unchanged. 
However, it is possible that N6-demethyl 1P-LSD (ID 13) was also generated during the 
metabolic transformation of 1P-ETH-LAD although it was not detected in the pS9 
incubations. In conclusion, N-deethyl 1P-LSD (ID 12) was the only metabolite that could only 
be formed from 1P-LSD and from no other LSD-type NPS investigated in this study. LSD 
could also be formed after intake of ALD-52 or 1B-LSD and in both cases, LSD and its 
metabolites were detected in the pS9 incubations. In case of ALD-52, the two specific 
metabolites N-deethyl ALD-52 (ID 9, PM at m/z 338.1863) and N6-demethyl ALD-52 (nor-
ALD-52) (ID 10, PM at m/z 352.2019) were additionally identified and in case of 1B-LSD, 
only hydroxy 1B-LSD (ID 15, PM at m/z 410.2438) was detected. These findings clearly 
demonstrated that urinary screening results have to be interpreted with care and that a positive 
urine screening result for LSD or its metabolites must not always be caused by an intake of 
LSD itself. 
12	
	
 
Proposed metabolic pathways 
The proposed metabolic pathways of 1P-LSD are given in Figure 3. The proposed metabolic 
pathways and MS2 data of the other compounds can be found in the electronic supplementary 
material (Fig. S1-S10).  
Monooxygenases activity screening and inhibition studies using selective CYP inhibitors  
In order to investigate the ability of monooxygenases to catalyze the initial metabolic phase I 
steps, an activity screening study using the ten most important CYP isoenzymes and FMO3 
was performed. Incubations with pHLM were used as control. These data are only qualitative 
and do not reflect a quantitative contribution of the investigated monooxygenases to hepatic 
clearance. Such an assessment requires the collection of enzyme kinetic data or inhibition 
experiments [31, 32, 49]. Results are listed in Table 2. CYP3A4 was found to be involved in 
the N6-demethylation of LSD, ALD-52, 1P-LSD, 1B-LSD, ECPLA, LSZ, and LSM-775, but 
also in the N6-deethylation of ETH-LAD and 1P-ETH-LAD and N6-deallylation of AL-LAD. 
Only in case of LSD, CYP2C19 showed additional N6-demethylation activity. CYP3A4 also 
catalyzed the N-deethylation of LSD and all other lysergamide test drugs, which resulted in 
the formation of N-mono ethylamide analog. Only CYP2C9 also catalyzed the N-deethylation 
of LSD and ECPLA. Aliphatic or aromatic hydroxylations were also catalyzed by CYP3A4 
for all investigated test drugs and additionally by CYP1A2 with the exception of the 1-
acylated LSD derivatives and ETH-LAD. CYP2D6 was found to be involved in the 
hydroxylation of ALD-52, 1B-LSD, and ETH-LAD. In pHLM incubations, the 1-deacylation 
of ALD-52, 1P-LSD, 1B-LSD, and 1P-ETH-LAD was additionally observed. However, this 
step was expected to be catalyzed by amidases and was not observed in incubations with the 
recombinant monooxygenases. In pHLM incubations with AL-LAD, ECPLA, and LSZ, also 
the corresponding lysergic acid metabolite was detected, and in case of ECPLA and LSZ, also 
lysergic acid amide. However, these metabolites could not be detected in incubations with 
recombinant enzymes and may also be the result of amidase-catalyzed reactions. 
The involvement of CYP1A2 and especially CYP3A4 in the metabolism of the investigated 
lysergamides is noteworthy. To confirm these results and to assess the importance of their 
contribution to the metabolism of these substances in the human liver, pHLM incubations in 
presence of selective CYP inhibitors were performed [32]. LSD, 1B-LSD, ETH-LAD, AL-
LAD, ECPLA, LSZ, and LSM-775 were incubated with the CYP1A2 inhibitor alpha-
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naphthoflavone, the CYP3A4 inhibitor ketoconazole or a mixture of them. For ALD-52, 1P-
LSD, 1B-LSD, ETH-LAD, and 1P-ETH-LAD, only ketoconazole was used because only 
CYP3A4 was shown to be involved in their initial metabolic steps. Results are summarized in 
Figure 4. Formation of CYP-dependent metabolites in reference incubations without inhibitor 
were set to 100% and compared to metabolite formation in incubations with inhibitor. For all 
test drugs, a significant reduction of metabolite formation in incubations with inhibitors was 
observed. In case of LSD, co-incubations with alpha-naphthoflavone decreased the metabolite 
formation by more than 50% and with ketoconazole and a mixture of both inhibitors by more 
than 80% in comparison to the incubations without inhibitor. Metabolite formation in co-
incubations of the 1-acylated lysergamides (ALD-52, 1P-LSD, 1B-LSD, and 1P-ETH-LAD) 
with ketoconazole was reduced by more than 80%. In case of ETH-LAD, ketoconazole led to 
a reduction of the metabolite formation by around 70%. The formation of AL-LAD, ECPLA, 
and LSZ metabolites was significantly increased by both inhibitors, alpha-naphthoflavone and 
ketoconazole, and co-incubations with their mixture resulted in a decrease of more than 70% 
in case of AL-LAD and around 90% for ECPLA and LSZ. Only in case of LSM-775, co-
incubations with alpha-naphthoflavone did not result in a statistically significant reduction of 
formed metabolites, in contrast to co-incubations with ketoconazole and their mixture that led 
to decreased metabolite formation of around 70% or 80%, respectively. Residual metabolite 
formations were most probably caused by incomplete enzyme inhibition and/or the 
involvement of further CYP isoforms in the metabolic transformation of the test drugs. 
Nevertheless, the inhibition experiments confirmed the importance of CYP1A2 and especially 
CYP3A4 in the metabolism of LSD analogs. CYP1A2 is known to be expressed 
polymorphically in humans, resulting in large interindividual variation of activity [50]. For 
example, polymorphisms resulting in lower CYP1A2 activity may lead to a decreased 
metabolic transformation of LSD-like substances that could result in an increased half-life of 
the drug. However, the results of the inhibition experiments suggest that CYP3A4 is even 
more important in the metabolism of LSD-related substances. Inhibition of CYP3A4 by co-
consumed drugs or food ingredients may also lead to decreased metabolic transformation. 
Nevertheless, LSD is not expected to exhibit remarkable acute toxicity [51, 52], but nothing is 
known about the toxicity of the LSD-based NPS. 
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Toxicological detectability 
For toxicological detectability studies, a dose of 0.01 mg/kg BW was administered to rats. 
Assuming a human BW of 60 kg, the doses corresponded to an expected recreational dose of 
136 µg in accordance to the dose by factor approach [53]. The SUSAs by GC-MS, LC-MSn, 
and LC-HRMS/MS were used and the results are briefly described in the following. 
GC-MS standard urine screening approach 
No metabolites or parent compounds could be identified in the rat urine by the GC-MS 
SUSA. This was most probably caused by the low stability of LSD and its derivatives against 
acidic hydrolysis and heat [54]. Nevertheless, the sample preparation was not changed as this 
is an established procedure used in toxicological routine analysis [55, 39]. Other reason could 
be minor excretion in rat urine and/or insufficient sensitivity of the used GC-MS apparatus. 
Also at and below 100 ng/mL of methanolic pure substance solutions, the GC-MS procedure 
was not able to detect the analytes. 
LC-MSn standard urine screening approach 
No metabolites or parent compounds could be identified in the rat urine by the LC-MSn 
SUSA. most probably caused by insufficient sensitivity. The LOIs using methanolic pure 
substance solutions were as follows: 1 ng/mL for 1P-LSD, 10 ng/mL for LSD, ALD-52, 
ETH-LAD, AL-LAD, ECPLA, LSZ, and LSM-775, and 100 ng/mL for 1B-LSD and 1P-
ETH-LAD. One reason for the lack of sensitivity might be the extremely broad peaks under 
the used standard conditions. 
LC-HRMS/MS standard urine screening approach 
Only a single ALD-52 metabolite, 1-deacetyl-N-deethyl ALD-52 (ID 2), was identified in the 
rat urine samples after a recreational user´s dose. However, this metabolite is not unique and 
can also be formed after intake of LSD, 1P-LSD, or 1B-LSD. No other metabolites or parent 
compounds could be identified by the LC-HRMS/MS SUSA. The LOIs using methanolic 
pure substance solutions were as follows: 1 ng/mL for LSD, 1P-LSD, ETH-LAD, AL-LAD, 
ECPLA, and LSZ, and 10 ng/mL for ALD-52, 1B-LSD, 1P-ETH-LAD, and LSM-775. 
Therefore, for detection and differentiation of an intake of LSD or its derivatives after 
expected recreational doses, a more selective sample workup, concentration step, and more 
selective MS settings, may help in detecting the parent drugs and/or unique metabolites 
identified in this study. For example solid-phase extraction by mixed-mode cartridges, 
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optionally after enzymatic conjugate cleavage, followed by LC-HRMS/MS using an adapted 
separation method and selective product ion scan or multiple-reaction monitoring should meet 
these requests. 
 
Conclusions 
The present study demonstrated that ALD-52, 1P-LSD, 1B-LSD, ETH-LAD, 1P-ETH-LAD, 
AL-LAD, ECPLA, LSZ, and LSM-775 were biotransformed to several phase I and few phase 
II metabolites in vitro. Many metabolites can originate from different parent compounds 
making their differentiation difficult, but this study also identified unique metabolites 
overcoming this problem. The mass spectral data obtained during these studies is essential for 
establishing reliable detection methods, especially for urinalysis. However, selective sample 
workup and MS settings are needed for reliable analytical detection and differentiation. 
CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 were found to be involved in the 
initial metabolic steps. Inhibition experiments confirmed the major influence of CYP1A2 and 
CYP3A4, therefore genetic polymorphisms of CYP1A2 might have an impact on the 
metabolism of these NPS. Furthermore, drug-drug or drug-food interactions might occur in 
case of co-consumption with CYP1A2 or CYP3A4 inhibitors resulting in decreased metabolic 
transformation of LSD analogs, but further investigations are needed for an assessment of 
possible clinical effects. The authors´ standard urine screening procedures are most likely not 
able to allow the detection of the studied NPS. Alternative analytical strategies need to be 
used instead. 
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Table 1: LSD, ALD-52, 1P-LSD, 1B-LSD, ETH-LAD, 1P-ETH-LAD, AL-LAD, ECPLA, LSZ, LSM-775, and 
their phase I and II metabolites along with their identification numbers (ID), the exact mass of the protonated 
molecule (M+H+), elemental composition, retention time (RT), and the three most abundant fragment ions (FI A-
C) in MS2 sorted by decreasing intensity. The parent compounds are given in bold and the metabolites were 
sorted by increasing mass and RT. 
 
ID Compound Exact 
mass, m/z 
Elemental 
composition 
RT, 
min 
FI A FI B FI C 
1 LSD 324.2070 C20H26N3O 5.3 223.1229 208.0995 281.1648 
2 N-Deethyl LSD 296.1757 C18H22N3O 3.3 223.1229 208.0756 253.1335 
3 N6-Demethyl LSD 310.1913 C19H24N3O 5.3 209.1073 74.0964 237.1022 
4 Hydroxy LSD isomer 1  340.2019 C20H26N3O2 3.4 221.1073 239.1184 322.1913 
5 Hydroxy LSD isomer 2  340.2019 C20H26N3O2 3.6 239.1184 297.1597 224.0706 
6 Dihydroxy LSD 356.1968 C20H26N3O3 2.5 237.1022 74.0964 313.1552 
7 Hydroxy LSD isomer 2 
glucuronide 
516.2340 C26H34N3O8 2.0 239.1184 340.2019 224.0706 
8 ALD-52 366.2176 C22H28N3O2 6.2 265.1335 223.1229 208.0756 
2 1-Deacetyl-N-deethyl 
ALD-52 
296.1757 C18H22N3O 3.3 223.1229 208.0756 253.1335 
3 1-Deacetyl-N6-demethyl 
ALD-52 
310.1913 C19H24N3O 5.3 209.1073 74.0964 237.1022 
1 1-Deacetyl ALD-52 324.2070 C20H26N3O 5.3 223.1229 208.0995 281.1648 
9 N-Deethyl ALD-52 338.1863 C20H24N3O2 4.5 265.1335 223.1229 295.1441 
4 1-Deacetyl-hydroxy 
ALD-52 isomer 1 
340.2019 C20H26N3O2 3.4 221.1073 239.1184 322.1913 
5 1-Deacetyl-hydroxy 
ALD-52 isomer 2 
340.2019 C20H26N3O2 3.6 239.1184 297.1597 224.0706 
10 N6-Demethyl ALD-52 352.2019 C21H26N3O2 6.2 251.1178 209.1073 74.0964 
11 1P-LSD 380.2332 C23H30N3O2 7.2 223.1229 279.1491 208.0756 
2 1-Depropionyl-N-
deethyl-1P-LSD 
296.1757 C18H22N3O 3.3 223.1229 208.0756 253.1335 
3 1-Depropionyl-N6-
demethyl 1P-LSD 
310.1913 C19H24N3O 5.3 209.1073 74.0964 237.1022 
1 1-Depropionyl 1P-LSD 324.2070 C20H26N3O 5.3 223.1229 208.0995 281.1648 
4 1-Depropionyl-hydroxy 
1P-LSD isomer 1 
340.2019 C20H26N3O2 3.4 221.1073 239.1184 322.1913 
5 1-Depropionyl-hydroxy 
1P-LSD isomer 2 
340.2019 C20H26N3O2 3.6 239.1184 297.1597 224.0706 
12 N-Deethyl 1P-LSD 352.2019 C21H26N3O2 5.6 223.1229 279.1491 208.0756 
6 1-Depropionyl-
dihydroxy 1P-LSD 
356.1968 C20H26N3O3 2.5 237.1022 74.0964 313.1552 
13 N6-Demethyl 1P-LSD 366.2176 C22H28N3O2 7.2 209.1073 265.1335 74.0964 
14 1B-LSD 394.2489 C24H32N3O2 8.0 293.1648 223.1229 208.0756 
2 1-Debutyryl-N-deethyl-
1B-LSD 
296.1757 C18H22N3O 3.3 223.1229 208.0756 253.1335 
3 1-Debutyryl-N6-
demethyl 1B-LSD 
310.1913 C19H24N3O 5.3 209.1073 74.0964 237.1022 
1 1-Debutyryl 1B-LSD 324.2070 C20H26N3O 5.3 223.1229 208.0995 281.1648 
4 1-Debutyryl-hydroxy 
1B-LSD isomer 1 
340.2019 C20H26N3O2 3.4 221.1073 239.1184 322.1913 
5 1-Debutyryl-hydroxy 
1B- LSD isomer 2 
340.2019 C20H26N3O2 3.6 239.1184 297.1597 224.0706 
6 1-Debutyryl-dihydroxy 356.1968 C20H26N3O3 2.5 237.1022 74.0964 313.1552 
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1B- LSD 
15 Hydroxy 1B-LSD 410.2438 C24H32N3O3 5.7 309.1597 223.1229 208.0995 
16 ETH-LAD 338.2226 C21H28N3O 5.6 237.1386 208.0995 309.1835 
17 N-Deethyl ETH-LAD  310.1913 C19H24N3O 3.6 237.1386 208.0995 281.1522 
3 N6-Deethyl ETH-LAD  310.1913 C19H24N3O 5.3 209.1073 74.0964 237.1022 
18 Hydroxy ETH-LAD 354.2176 C21H28N3O2 3.8 253.1335 297.1603 196.0762 
19 Dihydroxy ETH-LAD 370.2125 C21H28N3O3 2.8 251.1178 279.1128 313.1552 
20 Hydroxy ETH-LAD 
glucuronide 
530.2496 C27H36N3O8 2.4 253.1335 354.2176 325.1784 
21 1P-ETH-LAD 394.2489 C24H32N3O2 7.6 293.1648 237.1386 208.0756 
17 1-Depropionyl-N-deethyl 
1P-ETH-LAD  
310.1913 C19H24N3O 3.6 237.1386 208.0995 281.1522 
3 1-Depropionyl-N6-
deethyl 1P-ETH-LAD 
310.1913 C19H24N3O 5.3 209.1073 74.0964 237.1022 
16 1-Depropionyl 1P-ETH-
LAD 
338.2226 C21H28N3O 5.6 237.1386 208.0995 309.1835 
18 1-Depropionyl-hydroxy 
1P-ETH-LAD 
354.2176 C21H28N3O2 3.8 253.1335 297.1603 196.0762 
22 N-Deethyl 1P-ETH-LAD 366.2176 C22H28N3O2 5.9 293.1648 208.0995 237.1648 
19 1-Depropionyl-
dihydroxy 1P-ETH-LAD 
370.2125 C21H28N3O3 2.8 251.1178 279.1128 313.1552 
20 1-Depropionyl-hydroxy 
1P-ETH-LAD 
glucuronide 
530.2496 C27H36N3O8 2.4 253.1335 354.2176 325.1784 
23 AL-LAD 350.2226 C22H28N3O 6.2 208.0995 309.1835 182.0838 
24 N6-Deallyl-N-deethyl 
AL-LAD 
282.1600 C17H20N3O 3.2 209.1073 237.1027 134.0964 
25 N6-Allyl-norlysergic acid 295.1441 C18H19N2O2 2.9 70.0656 254.1049 238.0868 
3 N6-Deallyl AL-LAD 310.1913 C19H24N3O 5.3 209.1073 74.0964 237.1022 
26 N-Deethyl AL-LAD 322.1913 C20H24N3O 4.2 281.1522 208.0995 182.0838 
27 N-Deethyl-hydroxy AL-
LAD 
338.1863 C20H24N3O2 2.6 297.1471 225.1022 207.0916 
28 Hydroxy AL-LAD 
isomer 1 
366.2176 C22H28N3O2 3.8 224.0944 325.1784 198.0787 
29 Hydroxy AL-LAD 
isomer 2 
366.2176 C22H28N3O2 4.3 223.0871 325.1784 297.1603 
30 Hydroxy AL-LAD 
isomer 3 
366.2176 C22H28N3O2 5.0 207.0922 247.1235 265.1340 
31 Dihydroxy AL-LAD 
isomer 1 
382.2125 C22H28N3O3 3.3 221.0714 263.1178 313.1552 
32 Dihydroxy AL-LAD 
isomer 2 
382.2125 C22H28N3O3 4.1 128.1069 255.1133 223.0871 
33 Hydroxy AL-LAD 
isomer 1 glucuronide 
542.2496 C28H36N3O8 3.1 325.1784 224.0944 501.2105 
34 ECPLA 336.2070 C21H26N3O 6.0 223.1235 208.0756 86.0964 
35 Lysergic acid amide 268.1444 C16H18N3O 1.5 223.1235 208.0762 180.0813 
36 Lysergic acid 269.1284 C16H17N2O2 2.2 223.1235 254.1049 238.0868 
37 N-Deethyl ECPLA 308.1757 C19H22N3O 3.3 223.1235 208.0762 265.1340 
38 N6-Demethyl ECPLA 322.1913 C20H24N3O 5.9 209.1078 237.1027 86.0964 
39 
Hydroxy ECPLA  
isomer 1 
352.2019 C21H26N3O2 3.0 239.1184 224.0944 86.0964 
40 
Hydroxy ECPLA  
isomer 2 
352.2019 C21H26N3O2 4.0 239.1184 221.1078 334.1913 
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41 
Hydroxy ECPLA  
isomer 3 
352.2019 C21H26N3O2 4.2 239.1184 86.0964 224.0706 
42 Dihydroxy ECPLA  368.1968 C21H26N3O3 3.3 237.1027 222.0555 86.0964 
43 LSZ 336.2070 C21H26N3O 5.3 223.1235 140.1070 208.0995 
35 Lysergic acid amide 268.1444 C16H18N3O 1.5 223.1235 208.0762 180.0813 
36 Lysergic acid 269.1284 C16H17N2O2 2.2 223.1235 254.1049 238.0868 
44 
Hydroxy lysergic acid 
amide 284.1393 C16H18N3O2 1.0 221.1078 266.1287 239.1184 
45 N6-Demethyl LSZ 322.1913 C20H24N3O 5.2 209.1073 140.1070 237.1027 
46 Hydroxy LSZ isomer 1 352.2019 C21H26N3O2 3.7 239.1184 224.0711 140.1070 
47 Hydroxy LSZ isomer 2 352.2019 C21H26N3O2 3.9 221.1078 334.1913 249.1027 
48 Hydroxy LSZ isomer 3 352.2019 C21H26N3O2 4.3 208.0762 223.1235 334.1913 
49 Dihydroxy LSZ 368.1968 C21H26N3O3 2.8 237.1027 222.0555 265.0977 
50 
Hydroxy LSZ isomer 1 
glucuronide 
528.2340 C27H34N3O8 2.1 239.1184 352.2019 140.1070 
51 LSM-775 338.1863 C20H24N3O2 3.5 223.1235 208.0762 295.1446 
52 N6-Demethyl LSM-775 324.1706 C19H22N3O2 3,4 209.1078 237.1027 183.0922 
53 
Hydroxy LSM-775 
isomer 1 
354.1812 C20H24N3O3 1.5 221.1078 336.1706 249.1027 
54 
Hydroxy LSM-775 
isomer 2 
354.1812 C20H24N3O3 1.7 221.1078 336.1706 249.1027 
55 
Hydroxy LSM-775 
isomer 3 
354.1812 C20H24N3O3 2.1 239.1184 224.0706 311.1395 
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Table 2: General involvement of tested monooxygenases in the initial metabolic steps. n.d. = not detected 
Compound N6-Dealkylation N-Deethylation Hydroxylation 
LSD 
CYP2C19 
CYP3A4 
CYP2C9 
CYP3A4 
CYP1A2 
CYP3A4 
ALD-52 CYP3A4 CYP3A4 
CYP2D6 
CYP3A4 
1P-LSD CYP3A4 CYP3A4 CYP3A4 
1B-LSD CYP3A4 CYP3A4 
CYP2D6 
CYP3A4 
ETH-LAD CYP3A4 CYP3A4 
CYP2D6 
CYP3A4 
1P-ETH-LAD CYP3A4 CYP3A4 CYP3A4 
AL-LAD CYP3A4 CYP3A4 
CYP1A2 
CYP3A4 
ECPLA 
CYP2C19 
CYP3A4 
CYP2C9 
CYP3A4 
CYP1A2 
CYP3A4 
LSZ CYP3A4 n.d. 
CYP1A2 
CYP3A4 
LSM-775 CYP3A4 n.d. 
CYP1A2 
CYP3A4 
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Figures 
 
 
Fig. 1: Chemical structures of LSD and nine LSD-based new psychoactive substances. 
Structural changes in comparison to LSD are marked in red. 
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Fig. 2: HRMS/MS spectra and retention times (RT) of LSD (ID 1) and 1P-LSD (ID 11) as 
well as two of their metabolites (hydroxy LSD isomer 1, ID 4 and N-deethyl 1P-LSD, ID 12) 
to support described mass spectral based metabolite identification. Numbering according to 
Table 1. 
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Fig. 3: Postulated metabolic pathways of 1P-LSD studied by in vitro incubations with pooled 
human liver S9 fraction. Numbering according to Table 1. 
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Fig. 4: Percentage formation of CYP-dependent metabolites in pHLM co-incubations of LSD 
or LSD analogs with the selective CYP1A2 inhibitor alpha-naphthoflavone, the selective 
CYP3A4 inhibitor ketoconazole, or a mixture of both inhibitors. Formation in reference 
incubations without inhibitor was referred to as 100%. 
